Brenda Reynolds
Director/Board Member at iQur Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| William Rosenberg | M | - |
iQur Ltd.
 iQur Ltd. BiotechnologyHealth Technology iQur Ltd. develops vaccines based on tandem core vaccine technology. The firm offers fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programs. The company was founded by William Rosenberg on February 13, 2003 and is headquartered in London, the United Kingdom. | 21 years |
| David Campbell | M | 80 |
iQur Ltd.
iQur Ltd. BiotechnologyHealth Technology iQur Ltd. develops vaccines based on tandem core vaccine technology. The firm offers fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programs. The company was founded by William Rosenberg on February 13, 2003 and is headquartered in London, the United Kingdom. | 19 years |
| Charles Swingland | M | - |
Adiga Life Sciences, Inc.
 Adiga Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Adiga Life Sciences, Inc. operates as a healthcare company that conducts medical researches. It develops technologies to control immune function in allergic and auto immune diseases. The company was founded on November 25, 2008 and is headquartered in Hamilton, Canada. | - |
| John Tite | M | - |
iQur Ltd.
iQur Ltd. BiotechnologyHealth Technology iQur Ltd. develops vaccines based on tandem core vaccine technology. The firm offers fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programs. The company was founded by William Rosenberg on February 13, 2003 and is headquartered in London, the United Kingdom. | 15 years |
| Michael Underwood | M | - |
iQur Ltd.
iQur Ltd. BiotechnologyHealth Technology iQur Ltd. develops vaccines based on tandem core vaccine technology. The firm offers fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programs. The company was founded by William Rosenberg on February 13, 2003 and is headquartered in London, the United Kingdom. | 10 years |
| Ivo Timmermans | M | - |
Pleco Therapeutics BV
 Pleco Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans. | - |
| Debra Ainge | M | - |
Pleco Therapeutics BV
Pleco Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans. | - |
| Callum Meikle | M | - |
Pleco Therapeutics BV
Pleco Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans. | - |
| Susan Waserman | F | - |
Adiga Life Sciences, Inc.
Adiga Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Adiga Life Sciences, Inc. operates as a healthcare company that conducts medical researches. It develops technologies to control immune function in allergic and auto immune diseases. The company was founded on November 25, 2008 and is headquartered in Hamilton, Canada. | - |
| Gerard van Leijenhorst | M | - |
Pleco Therapeutics BV
Pleco Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans. | - |
| Brent Davis | M | - |
Adiga Life Sciences, Inc.
Adiga Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Adiga Life Sciences, Inc. operates as a healthcare company that conducts medical researches. It develops technologies to control immune function in allergic and auto immune diseases. The company was founded on November 25, 2008 and is headquartered in Hamilton, Canada. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jerry Christopher Benjamin | M | 83 |
PowderMed Ltd.
 PowderMed Ltd. Pharmaceuticals: MajorHealth Technology PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom. | - |
| Rolf Stahel | M | 79 |
PowderMed Ltd.
PowderMed Ltd. Pharmaceuticals: MajorHealth Technology PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom. | 1 years |
| Mark P. Carthy | M | 63 |
PowderMed Ltd.
PowderMed Ltd. Pharmaceuticals: MajorHealth Technology PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom. | - |
| Timothy Haines | M | 67 |
PowderMed Ltd.
PowderMed Ltd. Pharmaceuticals: MajorHealth Technology PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom. | - |
| Kate Bingham | F | 58 |
PowderMed Ltd.
PowderMed Ltd. Pharmaceuticals: MajorHealth Technology PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom. | - |
| Adam Christie | M | - |
PowderMed Ltd.
PowderMed Ltd. Pharmaceuticals: MajorHealth Technology PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom. | 4 years |
| David Gannaway | M | - |
PowderMed Ltd.
PowderMed Ltd. Pharmaceuticals: MajorHealth Technology PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 11 | 61.11% |
| Netherlands | 4 | 22.22% |
| Canada | 3 | 16.67% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Brenda Reynolds
- Personal Network
